Cytosorbents (NASDAQ:CTSO) Trading 5.2% Higher

Cytosorbents Corp (NASDAQ:CTSO) traded up 5.2% during mid-day trading on Wednesday . The stock traded as high as $5.20 and last traded at $5.42, 4,063 shares traded hands during mid-day trading. A decline of 98% from the average session volume of 256,137 shares. The stock had previously closed at $5.15.

Several equities analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating on shares of Cytosorbents in a report on Wednesday, August 7th. B. Riley set a $12.00 target price on Cytosorbents and gave the company a “buy” rating in a report on Friday, July 19th. ValuEngine cut Cytosorbents from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Maxim Group set a $14.00 price target on Cytosorbents and gave the stock a “buy” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $13.67.

The business’s fifty day moving average price is $5.45 and its 200 day moving average price is $6.70. The firm has a market capitalization of $155.38 million, a price-to-earnings ratio of -9.80 and a beta of 1.68. The company has a current ratio of 3.21, a quick ratio of 3.00 and a debt-to-equity ratio of 0.87.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.03. Cytosorbents had a negative net margin of 72.43% and a negative return on equity of 105.97%. The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.53 million. As a group, sell-side analysts forecast that Cytosorbents Corp will post -0.53 earnings per share for the current fiscal year.

In other Cytosorbents news, CFO Kathleen P. Bloch bought 6,500 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average price of $4.83 per share, for a total transaction of $31,395.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.60% of the stock is currently owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Cytosorbents during the first quarter worth $47,000. D. E. Shaw & Co. Inc. purchased a new position in Cytosorbents in the 2nd quarter valued at $164,000. Advisor Group Inc. increased its stake in Cytosorbents by 15.8% in the 2nd quarter. Advisor Group Inc. now owns 33,170 shares of the medical research company’s stock valued at $219,000 after buying an additional 4,530 shares during the period. Susquehanna International Group LLP raised its position in Cytosorbents by 933.4% during the 2nd quarter. Susquehanna International Group LLP now owns 38,447 shares of the medical research company’s stock worth $254,000 after buying an additional 43,060 shares during the last quarter. Finally, Rhumbline Advisers raised its position in Cytosorbents by 11.7% during the 1st quarter. Rhumbline Advisers now owns 42,589 shares of the medical research company’s stock worth $322,000 after buying an additional 4,454 shares during the last quarter. Institutional investors and hedge funds own 26.29% of the company’s stock.

About Cytosorbents (NASDAQ:CTSO)

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Featured Article: What does a bar chart mean for investors?

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with's FREE daily email newsletter.